Research Topics
| Xiaolin WanSummaryAffiliation: National Institutes of Health Country: USA Publications
|
Detail Information
Publications
Identification of FoxM1/Bub1b signaling pathway as a required component for growth and survival of rhabdomyosarcomaXiaolin Wan
Molecular Oncology Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
Cancer Res 72:5889-99. 2012..These results show the important role of the Bub1b/FoxM1 pathway in RMS and provide potential therapeutic targets...- Beta4 integrin promotes osteosarcoma metastasis and interacts with ezrinX Wan
Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892 1928, USA
Oncogene 28:3401-11. 2009..These data begin to integrate ezrin and beta4 integrin expression into a model of action for the mechanism of osteosarcoma metastases... - CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signalingXiaolin Wan
Molecular Oncology Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1928, USA
Neoplasia 8:394-401. 2006..Together, these data suggest that CCI-779 inhibits human RMS xenograft growth by an antiangiogenic mechanism associated with the targeting of mTOR/Hif-1alpha/VEGF signaling... 
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanismX Wan
Molecular Oncology Section, Pediatric Oncology Branch, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, MD 20892 1928, USA
Oncogene 26:1932-40. 2007..Thus, combining an mTOR inhibitor and an IGF-1R antibody/inhibitor may be an appropriate strategy to enhance mTOR-targeted anticancer therapy...- Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcomaXiaolin Wan
Molecular Oncology Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892-1106, USA
Cancer Res 65:2406-11. 2005..These results suggest that blocking the mTOR/S6K1/4E-BP1 pathway may be an appropriate target for strategies to reduce tumor cell metastasis... - The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasisChand Khanna
Pediatric Oncology Branch and Tissue Array Project Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Nat Med 10:182-6. 2004..High ezrin expression in dog tumors was associated with early development of metastases. Consistent with this data, we found a significant association between high ezrin expression and poor outcome in pediatric osteosarcoma patients... - Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibodyLiang Cao
Genetics Branch, Center for Cancer Research, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 4265, USA
Cancer Res 68:8039-48. 2008..Subsequent progression of tumors was associated with reactivation of p-AKT despite sustained suppression of IGF-IR. These results identified the first predictive biomarker for anti-IGF-IR therapies in cancer... - Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survivalEmanuel F Petricoin
Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Cellular and Gene Therapy, National Cancer Institute, NIH, Bethesda, Maryland, USA
Cancer Res 67:3431-40. 2007..These results suggest that phosphoprotein mapping of the Akt/mTOR pathway should be studied further as a means to select patients to receive mTOR/IRS pathway inhibitors before administration of chemotherapy... 
Targeting IGF-1R in the treatment of sarcomas: past, present and futureSu Young Kim
Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Bull Cancer 96:E52-60. 2009..In this review, we will focus on preclinical highlights in the past, current clinic trials and discuss some exciting research opportunities to foster advances in the future...- Levels of PTEN protein modulate Akt phosphorylation on serine 473, but not on threonine 308, in IGF-II-overexpressing rhabdomyosarcomas cellsXiaolin Wan
Molecular Oncology Section, Pediatric Oncology Branch, NCI, National Institutes of Health, Bethesda, MD 20892-1928, USA
Oncogene 22:8205-11. 2003..A better understanding of the pathway in RMS will likely contribute to insights into the biology of the RMS tumorigenesis and hopefully lead to novel therapeutic options... - The biology behind mTOR inhibition in sarcomaXiaolin Wan
Molecular Oncology Section, Pediatric Oncology Branch, Building 10, Room CRC 1W 3816, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1928, USA
Oncologist 12:1007-18. 2007..Disclosure of potential conflicts of interest is found at the end of this article... - Effect of insulin-like growth factor II on protecting myoblast cells against cisplatin-induced apoptosis through p70 S6 kinase pathwayXiaolin Wan
Molecular Oncology Section, Pediatric Oncology Branch, NCI, National Institutes of Health, Bethesda, MD 20892-1928, USA
Neoplasia 4:400-8. 2002..Thus, inhibition of the p70 S6 pathway may enhance chemotherapy-induced apoptosis in the treatment of IGF-II-overexpressing tumors...